Qicong Hu
Managing Director&Partner
Boston Consulting Group
Personal Profile
Qicong Hu is a Managing Director and Partner from BCG Shanghai office. He has extensive experience serving leading MNC and local biopharma, life science and Medtech client on high impact programs, with deep experience and expertise in the space of biopharma (R&D, product launch, biologics/biosimilars, and mkt access), Digital, BD and emerging therapies
Biopharma
New Product launch: strategy, operation uplift and acceleration
R&D: strategy, portfolio planning/upgrading and early-stage pipeline screening through AI and machine learning for leading local client
Digital: digital marketing, BI/DW, digital acceleration, digital capabilities including org and governance, data and analytics
R&D: governance, organization, and operations
Mkt access: strategy design and execution with deep understanding reimbursement pathway and Payer dynamics
Rich experience in Cell therapy and Gene therapy, supported leading MNC and Local companies in developing R&D, China entry and GTM strategies
Life science
Served top life science players on China strategies including market landscaping, GTM and digital strategies
BD/CD
Served local and MNC client to scout for innovation/targets and support in deal sourcing, cDD and deal transactions
Biologics/Biosimilars: author of Biologics White Paper with RDPAC, many case experiences in the space
Emerging therapies
R&D, manufacture, and commercialization of new technologies and treatment modalities, including cell and gene therapy
Other experience
Frequently invited as speakers to many biopharma, IVD and life science summit and symposia
Publish many high influence industry articles and papers including《RDPAC生物药白皮书》《新药上市战略进阶之路 》《医疗健康行业“疫情后”的六大转变》、《中国生物科技产业：政策、产品、资本与人才》、《中国生物科技发展下一个黄金十年，关键要素应如何把握》
Qicong Hu holds a Ph.D. from Stanford University in Biomedical Sciences
Published 8 articles in World renowned journals including first author in "Science", chosen as one of top 5 articles that year by "Faculty of 1000".
Experience and expertise includes
New Product launch: strategy, operation uplift and acceleration
R&D: strategy, portfolio planning/upgrading and early-stage pipeline screening through AI and machine learning for leading local client
Digital: digital marketing, BI/DW, digital acceleration, digital capabilities including org and governance, data and analytics
R&D: governance, organization, and operations
Mkt access: strategy design and execution with deep understanding reimbursement pathway and Payer dynamics
Rich experience in Cell therapy and Gene therapy, supported leading MNC and Local companies in developing R&D, China entry and GTM strategies
Life science
Served top life science players on China strategies including market landscaping, GTM and digital strategies
BD/CD
Served local and MNC client to scout for innovation/targets and support in deal sourcing, cDD and deal transactions
Biologics/Biosimilars: author of Biologics White Paper with RDPAC, many case experiences in the space
Emerging therapies
R&D, manufacture, and commercialization of new technologies and treatment modalities, including cell and gene therapy
Publish many high influence industry articles and papers including《RDPAC生物药白皮书》《新药上市战略进阶之路 》《医疗健康行业“疫情后”的六大转变》、《中国生物科技产业：政策、产品、资本与人才》、《中国生物科技发展下一个黄金十年，关键要素应如何把握》
Qicong Hu holds a Ph.D. from Stanford University in Biomedical Sciences
Published 8 articles in World renowned journals including first author in "Science", chosen as one of top 5 articles that year by "Faculty of 1000".
